General
Preferred name
NVS-CECR2-1
Synonyms
NVS-1 ()
P&D ID
PD000029
CAS
1992047-61-6
Tags
available
probe
Probe info
Probe selectivity
protein-selective
Probe type
P&D approved
experimental probe
Probe sources
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION NVS-1 is a small-molecule selective inhibitor of the bromodomain-containing protein cat eye syndrome chromosome region, candidate 2 (CECR2) . NVS-1 is one of the compounds available from the Structural Genomics Consortium's epigenetic probes set. It was developed in collaboration with Novartis. (GtoPdb)
MOA Inhibitor (Chemical Probes.org)
DESCRIPTION Gene switch ligand for use in inducible gene expression systems (Tocris Bioactive Compound Library)
DESCRIPTION NVS-CECR2-1 is a potent and selective CECR2 (cat eye syndrome chromosome region, candidate 2) inhibitor (IC50 = 47 nM). NVS-CECR2-1 showed no cross reactivity in a BRD panel of 48 targets or any major activity in kinase, protease and receptor panels. CECR2 (cat eye syndrome chromosome region, candidate 2) is a component of chromatin complexes that regulate gene expression controlling development. (BOC Sciences Bioactive Compounds)
Compound Sets
12
BOC Sciences Bioactive Compounds
Bromodomains chemical toolbox
Cayman Chemical Bioactives
Chemical Probes.org
CZ-OPENSCREEN Bioactive Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
High-quality chemical probes
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
SGC Probes
Tocris Bioactive Compound Library
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
495.27
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
3
cLogP
5.34
TPSA
88.91
Fraction CSP3
0.56
Chiral centers
0.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Primary Target
Bromodomains
MOA
Inhibitor
CECR2 inhibitor
CECR2 inhbitor
Member status
member
Pathway
Apoptosis
Epigenetics
Target
Epigenetic Reader Domain
CECR2
Solubility
DMSO to 100 mM
Target class
Epigenetic
Target subclass
Bromodomain
Control
NVS-CECR2-C
Recommended Cell Concentration
1 µM
Source data